NASD · Healthcare · Biotechnology · Netherlands
uniQure NV is a small cap company (market value between $300 million and $2 billion) in the Biotechnology industry.
uniQure NV develops gene therapy treatments targeting rare and severe disorders. The company has a pipeline of clinical-stage candidates for Huntington's disease, refractory mesial temporal lobe epilepsy, Fabry disease, and SOD1-ALS, aiming to provide one-time administered therapies with potential curative outcomes for patients with unmet medical needs.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the uniQure NV stock.
Overvalued: intrinsic value $0.43 per share, market price $24.83, margin of safety -5645.3% (as of 2026-10-30).
Its liquidation floor, current assets minus every liability, values the shares at $0.43; the price of $24.83 is 5645% above that value.
Leak Score: 29/100 on 9 of 12 signals (On Watch).
16 more funds hold it; the full list is part of the paid plan.
130 more in this industry show a wider margin of safety.
QURE is overvalued (as of the 2026-10-30 close). Its liquidation floor, current assets minus every liability, values the shares at $0.43; the price of $24.83 is 5645% above that value.
$0.43 per share (as of the 2026-10-30 close), against a market price of $24.83. That is a margin of safety of -5645.3%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
29 out of 100, which we rate "On Watch", on 9 of 12 value investing signals.